Quarterly report pursuant to Section 13 or 15(d)

Licenses Acquired - Additional Information (Detail)

v3.7.0.1
Licenses Acquired - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended
Apr. 25, 2017
Mar. 31, 2017
Feb. 17, 2017
Jan. 31, 2017
Mar. 31, 2017
Mar. 31, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Research And Development In Process         $ 1,294,000 $ 83,000
City Of Hope [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Payments for Fees     $ 100,000      
Revenue Recognition Milestone Method Payments Due     100,000      
Jubilant Biosys Ltd [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Research And Development In Process   $ 400,000        
Royalty Revenue   200,000     $ 500,000  
National Institute of Child Health and Human Development [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Payment of Upfront Milestone Fees   $ 100,000        
Columbia University [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Stock Issued During Period, Shares, Purchase of Assets       1,050,000    
Shares Issued, Price Per Share   $ 0.028     $ 0.028  
Stock Issued During Period, Value, Purchase of Assets         $ 29,000  
Payment of Upfront Milestone Fees       $ 200,000    
Revenue Recognition Milestone Method Payments Due       $ 5,500,000    
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners       10.00%    
Collaborative Agreements with TGTX [Member] | NeuPharma [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Payments for Fees         28,000 17,000
Checkpoint Therapeutics, Inc [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Research And Development In Process         $ 400,000 $ 0
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners   62.40% [1]     62.40% [1] 62.70%
Checkpoint Therapeutics, Inc [Member] | Dana-Farber [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Stock Issued During Period, Value, Purchase of Assets         $ 1,300,000  
UCLA License [Member] | University of California [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Payment of Upfront Fees $ 200,000          
A&R CD123 License [Member] | City Of Hope [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Revenue Recognition Milestone Method Payments Due     14,500,000      
A&R IL-13 License [Member] | City Of Hope [Member]            
Research and Development Arrangement, Contract to Perform for Others [Line Items]            
Research And Development In Process         $ 300,000  
Revenue Recognition Milestone Method Payments Due     $ 14,500,000      
[1] Checkpoint is consolidated with Fortress’s operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A common shares which provide for super-majority voting rights.